Truist Securiti Research Analysts Increase Earnings Estimates for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD) – Stock analysts at Truist Securiti increased their FY2021 earnings per share (EPS) estimates for shares of Affimed in a research report issued to clients and investors on Monday, November 22nd. Truist Securiti analyst S. Devarakonda now forecasts that the biopharmaceutical company will earn ($0.53) per share for the year, up from their previous forecast of ($0.54). Truist Securiti also issued estimates for Affimed’s FY2022 earnings at ($0.90) EPS, FY2023 earnings at ($1.11) EPS and FY2024 earnings at ($0.81) EPS.

A number of other analysts also recently issued reports on the stock. SVB Leerink restated a “buy” rating and set a $12.00 price target on shares of Affimed in a report on Sunday, November 14th. Zacks Investment Research upgraded shares of Affimed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 14th. Berenberg Bank assumed coverage on shares of Affimed in a research report on Wednesday, November 17th. They set a “buy” rating for the company. Stifel Nicolaus assumed coverage on shares of Affimed in a research report on Wednesday, September 29th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Truist assumed coverage on shares of Affimed in a research report on Thursday, October 21st. They set a “buy” rating and a $10.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $12.13.

Shares of NASDAQ AFMD opened at $7.07 on Thursday. The company has a 50 day simple moving average of $6.29 and a 200-day simple moving average of $7.05. The company has a market capitalization of $694.89 million, a P/E ratio of -12.85 and a beta of 2.58. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.07 and a quick ratio of 3.06. Affimed has a 1 year low of $4.78 and a 1 year high of $11.74.

Affimed (NASDAQ:AFMD) last announced its quarterly earnings results on Wednesday, November 10th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.01). Affimed had a negative return on equity of 40.23% and a negative net margin of 132.18%. During the same quarter last year, the company posted ($0.08) EPS.

Hedge funds have recently modified their holdings of the business. Meeder Asset Management Inc. purchased a new position in Affimed in the 2nd quarter valued at approximately $71,000. HighTower Advisors LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $85,000. Schonfeld Strategic Advisors LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $88,000. Boothbay Fund Management LLC purchased a new position in Affimed in the 2nd quarter valued at approximately $90,000. Finally, Lindbrook Capital LLC boosted its position in Affimed by 30.0% in the 2nd quarter. Lindbrook Capital LLC now owns 11,700 shares of the biopharmaceutical company’s stock valued at $99,000 after buying an additional 2,700 shares during the period. 73.02% of the stock is owned by institutional investors.

About Affimed

Affimed NV engages in the discovery and development of cancer immunotherapies. It offers ROCK novel proprietary antibody platform, which delivers types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. It operates through the following geographical segments: Germany, Europe, and USA.

Further Reading: Quantitative Easing

Earnings History and Estimates for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.